Juvelook Volume Collagen Biostimulator in Korea

PDLLA Microspheres and Fibroblast Activation

Juvelook Volume’s active biostimulating component is poly-D,L-lactic acid (PDLLA) microspheres measuring 150-250 micrometers in diameter. Upon injection into the deep dermis or subcutaneous layer, these microspheres create a controlled foreign body response that activates local fibroblasts. Unlike the aggressive inflammatory response seen with some materials, PDLLA triggers a mild, productive inflammatory cascade characterized by macrophage recruitment and fibroblast proliferation. The microspheres act as scaffolds around which fibroblasts deposit new type I and type III collagen in organized fibrillar networks. This process — termed neocollagenesis — produces volume that is biologically the patient’s own tissue, explaining why Juvelook Volume results feel natural to the touch and move naturally with facial expressions.

Dual-Mechanism Design: HA Carrier + PDLLA Stimulator

Juvelook Volume’s innovation lies in combining two established technologies in a single product. The cross-linked hyaluronic acid carrier gel provides immediate volumizing effect upon injection — patients see results on treatment day. Embedded within this HA matrix are PDLLA microspheres that begin their collagen-stimulating action over the following weeks. As the HA carrier gradually degrades (3-6 months), newly formed collagen takes over the volumizing role. This transition period is seamless — the patient experiences continuous volume rather than the gap between filler dissolution and biostimulation onset that occurs with pure PLLA products like Sculptra. Vleggaar and Bauer (2004) first described PLLA’s neocollagenesis mechanism, and subsequent studies by Goldberg et al. (2013) demonstrated that PDLLA variants offer faster, more predictable collagen formation due to the D,L-racemic configuration’s hydrolysis kinetics.

PDLLA Biodegradation and Long-Term Safety

PDLLA microspheres are fully biocompatible and biodegradable. Hydrolytic degradation converts PDLLA into lactic acid monomers — a natural metabolite produced by every cell in the body during normal glycolysis. The degradation timeline is predictable: microspheres begin breaking down at approximately 6-8 months post-injection and are completely absorbed by 12-18 months. Crucially, the collagen scaffold they stimulated remains intact after microsphere absorption, providing structural volume for 18-24 months total. This is the key advantage over HA fillers — with Juvelook Volume, the volume-providing structure (collagen) is permanent tissue, not a synthetic gel. Only the stimulating agent (PDLLA) is temporary. Lam et al. (2006) confirmed the favorable safety profile of poly-lactic acid microspheres in aesthetic applications, with nodule formation rates below 2% when proper injection technique and post-treatment massage are employed.

Clinical Outcomes and Combination Approaches

At RE:BERRY, Juvelook Volume is often combined with other treatments for comprehensive facial rejuvenation. Standard Juvelook skin booster addresses texture and hydration in the superficial dermis, while Juvelook Volume restores deeper structural volume. Rejuran Healer enhances tissue quality in areas where Juvelook Volume provides volume. For patients with significant laxity, combining Juvelook Volume with Sofwave or Onda lifting addresses both volume loss and skin tightening simultaneously — treating the two primary components of facial aging.

References: Vleggaar D, Bauer U. Dermatol Surg. 2004;30(12 Pt 2):1576-1583. doi:10.1111/j.1524-4725.2004.30551.x | Goldberg D et al. J Cosmet Laser Ther. 2013;15(3):134-142. doi:10.3109/14764172.2013.764435 | Lam SM et al. Facial Plast Surg. 2006;22(3):178-190. doi:10.1055/s-2006-950176